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MaBACKGROUND Neutrophil counts are a ubiquitous measure of inﬂammation, but previous studies on their association
with cardiovascular disease (CVD) were limited by small numbers of patients or a narrow range of endpoints.
OBJECTIVES This study investigated associations of clinically recorded neutrophil counts with initial presentation for a
range of CVDs.
METHODS We used linked primary care, hospitalization, disease registry, and mortality data in England. We included
people 30 years or older with complete blood counts performed in usual clinical care and no history of CVD. We used Cox
models to estimate cause-speciﬁc hazard ratios (HRs) for 12 CVDs, adjusted for cardiovascular risk factors and acute
conditions affecting neutrophil counts (such as infections and cancer).
RESULTS Among 775,231 individuals in the cohort, 154,179 had complete blood counts performed under acute conditions
and 621,052 when they were stable. Over a median 3.8 years of follow-up, 55,004 individuals developed CVD. Adjusted
HRs comparing neutrophil counts 6 to 7 versus 2 to 3  109/l (both within the ‘normal’ range) showed strong associations
with heart failure (HR: 2.04; 95% conﬁdence interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI:
1.72 to 2.21), unheralded coronary death (HR: 1.78; 95%CI: 1.51 to 2.10), abdominal aortic aneurysm (HR: 1.72; 95% CI: 1.34
to 2.21), and nonfatal myocardial infarction (HR: 1.58; 95% CI: 1.42 to 1.76). These associations were linear, with greater
risk even among individuals with neutrophil counts of 3 to 4 versus 2 to 3  109/l. There was a weak association with
ischemic stroke (HR: 1.36; 95% CI: 1.17 to 1.57), but no association with stable angina or intracerebral hemorrhage.
CONCLUSIONS Neutrophil counts were strongly associated with the incidence of some CVDs, but not others, even
within the normal range, consistent with underlying disease mechanisms differing across CVDs. (White Blood Cell Counts
and Onset of Cardiovascular Diseases: a CALIBER Study [CALIBER]; NCT02014610) (J Am Coll Cardiol 2017;69:1160–9)
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AND ACRONYM S
CI = conﬁdence interval
CVD = cardiovascular disease
HF = heart failure
HR = hazard ratio
IQR = interquartile range
MI = myocardial infarction
PAD = peripheral arterial
seT he most numerous type of white blood cell,neutrophils, play a major role in inﬂamma-tion. Neutrophil count is used routinely as a
biomarker of acute infection and inﬂammation, but
not in cardiology. Chronic inﬂammation contributes
to atherosclerosis and cardiovascular diseases (CVD)
(1,2) but, compared with other inﬂammatory bio-
markers such as C-reactive protein (3) and
interleukin-6 (4), neutrophil counts have been little
studied in relation to long-term CVD risk, even
though they are available at scale in clinically
collected electronic health record data.
Previous studies have shown that high neutrophil
counts are associated with an higher incidence of
coronary disease (5), heart failure (HF) (6), and stroke
(7) (Online Table 1). However, these studies were too
small to examine thresholds or shape of the associa-
tion. No study used a clinically recorded measure of
neutrophil count, which is important to understand
the relevance of ﬁndings to usual practice, or studied
associations with peripheral vascular diseases.SEE PAGE 1170This study investigated the association of neutro-
phil counts with initial presentation of 12 CVDs in a
large, population-based cohort from a linked elec-
tronic health record database: the CALIBER program
(Clinical Research Using Linked Bespoke Studies and
Electronic Health Records) (8). CALIBER has been
extensively validated, replicating known prospective
associations of CVDs with sex (9), smoking (10), blood
pressure (11), socioeconomic deprivation (12), and
type 2 diabetes (13).
METHODS
We used the same study cohort as our study on the
association of eosinophil and lymphocyte counts with
incidence of CVD (14). The study population was
drawn from the CALIBER program (8), which links 4
sources of electronic health data in England: primary
care health records (coded diagnoses, clinical mea-
surements, and prescriptions) from 244 general prac-
tices contributing to the Clinical Practice Research
Datalink; coded hospital discharges (Hospital Episode
Statistics); the Myocardial Ischemia National Audit
Project (MINAP); and death registrations (Online
Appendix). CALIBER includes about 4% of the popu-
lation of England (15) and is representative in terms
of age, sex, ethnicity, and mortality (8).
The study period was January 1998 to March 2010,
and individuals were eligible for inclusion when they
were at least 30 years of age and had been registeredfor at least 1 year in a practice that met
research data recording standards. The study
start date (index date) for each participant
was the date of the ﬁrst complete blood count
recorded in the primary care record while the
participant was eligible. Persons with a prior
history of CVD and women with a pregnancy
record within 6 months of the start of the
study were excluded.
Approval was granted by the Independent
Scientiﬁc Advisory Committee of the Medi-
cines and Healthcare Products Regulatory Agency
(protocol 12_153R) and the MINAP Academic Group.
The main exposure was the neutrophil count
(part of the complete blood count) as recorded in
primary care. We investigated the neutrophil count
initially as a categorical variable to avoid assuming a
particular shape for association with CVD. We wished
to speciﬁcally look at associations with ‘normal’ as
well as extreme neutrophil counts; there is no
consensus deﬁnition for the normal range, but many
laboratories quote the range of 2 to 7  109/l (16). This
lent itself to convenient 5-level categorization within
the ‘normal’ range. All category intervals were closed
at the lower bound and open at the upper bound
(i.e., ‘2 to 3’ includes 2 but not 3).
White cell counts can be affected by infections,
autoimmune diseases, medication, and hematologic
conditions. We classiﬁed the patient state at the time
of the blood test as acute or stable. An acute clinical
state was deﬁned as any of the following conditions:
in hospital on the date of blood test; vaccination in the
previous 7 days; anemia diagnosis within the previous
30 days; symptoms or diagnosis of infection within
the previous 30 days; prior diagnosis of myelodys-
plastic syndrome; hemoglobinopathy, cancer chemo-
therapy, or injection of granulocyte colony-
stimulating factor within the previous 6 months; or
the use of drugs affecting the immune system, such
as methotrexate or steroids, within the previous
3 months. Patients were considered stable if they
did not fulﬁll the criteria for an acute clinical state.
Patients on dialysis, those with human immunodeﬁ-
ciency virus infection, or a history of splenectomy
were excluded from this study, because their neutro-
phil counts may be difﬁcult to interpret. These criteria
were based on those proposed by the eMERGE (Elec-
tronic Medical Records and Genomics) consortium for
studying the genetic determinants of white cell
counts (17) (further details in the Online Appendix).
In secondary analyses, we explored associations
between onset of CVD and the mean of the ﬁrst 2
stable measurements of neutrophil count taken since
the start of eligibility. We extracted demographic
disea
TABLE 1 Patient Characteristics*
Neutrophil Count
p Value
for TrendBelow Normal Range Within Normal Range Above Normal Range
Neutrophils,  109/l <2 2–3 3–6 6–7 $7
N 26,588 154,863 489,143 48,849 55,788
Female 16,592 (62.4) 89,956 (58.1) 288,221 (58.9) 31,465 (64.4) 35,722 (64.0) <0.0001
Age, yrs 51.3 (40.6–61.8) 53 (42.2–63.1) 52.9 (42.0–65.3) 49.8 (38.8–65) 48.2 (36.9–64.7) <0.0001
Most deprived quintile 4,513 (17.0) 21,722 (14.1) 84,740 (17.4) 10,158 (20.9) 11,838 (21.3) <0.0001
Acute condition at time
of blood test
5,670 (21.3) 26,932 (17.4) 92,969 (19.0) 11,600 (23.7) 17,008 (30.5) <0.0001
Ethnicity
White 12,945 (80.3) 82,468 (90.8) 283,495 (93.5) 30,174 (94.5) 35,952 (95.4) <0.0001
South Asian 327 (2.0) 2,482 (2.7) 9,083 (3.0) 813 (2.5) 745 (2.0) <0.0001
Black 2,229 (13.8) 3,224 (3.6) 3,936 (1.3) 310 (1.0) 275 (0.7) <0.0001
Other 626 (3.9) 2,624 (2.9) 6,740 (2.2) 620 (1.9) 710 (1.9) <0.0001
Missing 10,461 (39.3) 64,065 (41.4) 185,889 (38.0) 16,932 (34.7) 18,106 (32.5) <0.0001
Full blood count parameters on index date
Eosinophils,  109/l 0.1 (0.09–0.2) 0.13 (0.1–0.2) 0.2 (0.1–0.27) 0.2 (0.1–0.3) 0.16 (0.1–0.27) <0.0001
Lymphocytes,  109/l 1.7 (1.36–2.07) 1.8 (1.5–2.2) 2.0 (1.61–2.49) 2.1 (1.69–2.7) 2.05 (1.58–2.63) <0.0001
Monocytes,  109/l 0.34 (0.29–0.42) 0.4 (0.3–0.5) 0.5 (0.4–0.6) 0.6 (0.5–0.74) 0.7 (0.5–0.9) <0.0001
Basophils,  109/l 0.01 (0–0.03) 0.02 (0–0.05) 0.03 (0–0.08) 0.03 (0–0.1) 0.03 (0–0.1) <0.0001
Hemoglobin, g/dl 13.5 (12.6–14.5) 13.9 (13–14.8) 14.0 (13.1–15) 13.8 (12.8–14.9) 13.7 (12.4–14.8) <0.0001
Platelets,  109/l 225 (190–263) 241 (207–279) 262 (224–306) 286 (242–338) 298 (249–360) <0.0001
Smoking status
Never 16,657 (66.1) 91,447 (62.1) 240,087 (51.7) 18,758 (40.7) 19,753 (37.7) <0.0001
Former 5,798 (23.0) 36,839 (25.0) 114,129 (24.6) 9,736 (21.1) 10,697 (20.4) <0.0001
Current 2,754 (10.9) 18,938 (12.9) 109,796 (23.7) 17,615 (38.2) 21,918 (41.9) <0.0001
Missing 1,379 (5.2) 7,639 (4.9) 25,131 (5.1) 2,740 (5.6) 3,420 (6.1) <0.0001
Most recent value within 1 yr before the index date
Systolic BP 131 (120–145) 135 (120–148) 138 (123–150) 135 (120–150) 130 (120–146) <0.0001
BMI 25.4 (22.7–28.7) 26.3 (23.4–29.8) 27.4 (24.1–31.5) 27.1 (23.4–32.1) 26.4 (22.9–31.1) <0.0001
Total cholesterol 5.4 (4.7–6.2) 5.5 (4.8–6.3) 5.5 (4.8–6.2) 5.3 (4.6–6.1) 5.3 (4.5–6.1) <0.0001
HDL cholesterol 1.53 (1.24–1.9) 1.47 (1.20–1.79) 1.35 (1.10–1.62) 1.30 (1.08–1.60) 1.3 (1.07–1.59) <0.0001
eGFR 84.4 (71.9–97.4) 82.8 (70.7–95.2) 81.4 (68.3–94.5) 82.4 (67.7–96.7) 83.1 (67.3–97.5) <0.0001
Diagnoses on or before index date
Atrial ﬁbrillation 176 (0.7) 1,044 (0.7) 5,169 (1.1) 602 (1.2) 731 (1.3) <0.0001
Cancer 2,089 (7.9) 9,343 (6.0) 29,468 (6.0) 2,863 (5.9) 3,758 (6.7) 0.2
Diabetes 860 (3.2) 5,322 (3.4) 25,081 (5.1) 2,896 (5.9) 2,968 (5.3) <0.0001
Asthma 2,721 (10.2) 17,046 (11.0) 61,521 (12.6) 7,165 (14.7) 8,344 (15.0) <0.0001
COPD 178 (0.7) 1,329 (0.9) 9,545 (2.0) 1,614 (3.3) 2,355 (4.2) <0.0001
Connective tissue disease 596 (2.2) 3,057 (2.0) 13,585 (2.8) 2,007 (4.1) 2,614 (4.7) <0.0001
IBD 207 (0.8) 1,316 (0.8) 5,377 (1.1) 717 (1.5) 1,029 (1.8) <0.0001
Medication use in the year before index date
Antihypertensives 5,342 (20.1) 34,000 (22.0) 130,791 (26.7) 13,255 (27.1) 13,893 (24.9) <0.0001
Statins 1,141 (4.3) 8,120 (5.2) 31,713 (6.5) 3,010 (6.2) 2,822 (5.1) <0.0001
Values are n (%) or median (interquartile range) unless otherwise indicated. *Completeness of recording of continuous variables at any time (as used for imputation) was 98.8%
for BP, 90.6% for body mass index, 58.9% for HDL and total cholesterol, and 57.1% for eGFR. Completeness of recording of these variables within 1 year before the index date
was 65.4%, 31.3%, 31.6%, and 47.0%, respectively. Diagnoses of comorbid conditions were considered completely recorded (i.e., absence of a diagnosis code was interpreted
as absence of the condition).
BMI ¼ body mass index; BP ¼ blood pressure; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein;
IBD ¼ inﬂammatory bowel disease.
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and acute conditions and prescriptions around the
time of the blood test from the primary care record.
For continuous covariates, we used the most recent
value in the year before or up to 1 day after the
complete blood count measurement. We alsoextracted the ﬁrst measurement after this time win-
dow and the last measurement before the time win-
dow, along with the timing of these measurements
relative to the index date, to use as auxiliary variables
for multiple imputation. We also used comorbidity
information from hospitalization records.
FIGURE 1 Cumulative Incidence Curves
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For cardiovascular presentations among people without prior cardiovascular disease (CVD), crude cumulative incidence curves are shown for the highest and lowest
categories of neutrophil count within the normal range. An artefact of imprecise coding rather than a clinical diagnosis, ‘nonspeciﬁc coronary disease’ was combined
with unstable angina. Similarly, nonspeciﬁc stroke was combined with ischemic stroke. The plots show that, for myocardial infarction, heart failure, ischemic stroke,
peripheral arterial disease (PAD), and abdominal aortic aneurysm, the incidence was greater among people with higher neutrophil counts.
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1163Individuals were followed until initial presentation
of CVD, death, or transfer out of the practice. The
primary endpoint was the ﬁrst record of 1 of the
following 12 initial cardiovascular presentations in any
of the data sources: coronary artery disease (stable
angina, unstable angina, nonfatal myocardial infarc-
tion [MI], unheralded coronary death), HF, transient
ischemic attack, ischemic or hemorrhagic stroke,
subarachnoid hemorrhage, peripheral arterial disease
(PAD), abdominal aortic aneurysm, or a composite of
ventricular arrhythmia, implantable cardioverter-
deﬁbrillator, cardiac arrest, or sudden cardiac death.
Nonspeciﬁc coronary artery disease and nonspeciﬁc
stroke were also included in the analysis as 2 addi-
tional endpoints, although they are artefacts of
imprecise coding rather than separate disease entities.
Any events occurring after the ﬁrst cardiovascular
presentation were ignored. Endpoint deﬁnitions are
described in the Online Appendix and phenotypingalgorithms are available on the CALIBER web portal
(website in the Online Appendix). We analyzed all-
cause mortality and a composite of all initial cardio-
vascular presentations as secondary endpoints.
STATISTICAL ANALYSIS. We examined associations
of CVD with neutrophil counts initially as a categori-
cal variable. If the shape of the association was found
to be linear, we also performed analyses with
neutrophil count as a continuous variable. We
generated cumulative incidence curves by category of
neutrophil count under a competing risks framework.
We used Cox proportional hazards models to estimate
cause-speciﬁc hazards for each of the 14 cardiovas-
cular endpoints. Hazard ratios (HRs) were adjusted
for age (linear and quadratic), sex, age–sex interac-
tion, index of multiple deprivation, ethnicity, smok-
ing status, diabetes, body mass index, systolic blood
pressure, estimated glomerular ﬁltration rate, high-
density lipoprotein cholesterol, total cholesterol,
FIGURE 2 Association of Neutrophil Count With Initial CVD Presentation
Hazard ratio (95% CI) Hazard ratio (95% CI)Initial presentation
Stable angina
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.94 (0.82-1.08)
1 (reference)
1.00 (0.94-1.06)
1.00 (0.94-1.06)
1.05 (0.97-1.13)
0.97 (0.88-1.07)
0.92 (0.83-1.01)
Transient ischemic attack
Initial presentation
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.96 (0.78-1.17)
1 (reference)
1.13 (1.03-1.23) *
1.10 (1.01-1.21) *
1.21 (1.09-1.34) **
0.32 (1.16-1.49) ***
1.25 (1.10-1.42) **
Unstable angina
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.94 (0.73-1.21)
1 (reference)
1.01 (0.91-1.13)
0.97 (0.86-1.09)
1.10 (0.96-1.26)
1.00 (0.84-1.19)
1.02 (0.86-1.22)
Ischemic stroke
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.05 (0.83-1.33)
1 (reference)
1.07 (0.97-1.19)
1.14 (1.02-1.27) *
1.29 (1.15-1.46) ***
1.36 (1.17-1.57) ***
1.32 (1.14-1.53) **
Coronary disease not further specified
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.02 (0.85-1.23)
1 (reference)
0.95 (0.88-1.03)
0.95 (0.87-1.04)
1.04 (0.94-1.16)
0.88 (0.76-1.01)
1.01 (0.88-1.16)
Stroke not further specified
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.15 (0.91-1.44)
1 (reference)
1.15 (1.03-1.28) *
1.37 (1.23-1.53) ***
1.47 (1.31-1.66) ***
1.71 (1.49-1.96) ***
1.71 (1.50-1.96) ***
Non fatal myocardial infarction
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.89 (0.72-1.09)
1 (reference)
1.17 (1.08-1.27) **
1.31 (1.21-1.43) ***
1.34 (1.22-1.48) ***
1.58 (1.42-1.76) ***
1.64 (1.47-1.82) ***
Subarachnoid hemorrhage
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.30 (0.82-2.06)
1 (reference)
0.86 (0.66-1.10)
0.93 (0.71-1.21)
0.87 (0.63-1.19)
1.16 (0.81-1.65)
1.37 (0.98-1.91)
Unheralded coronary death
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.83 (0.59-1.16)
1 (reference)
1.11 (0.98-1.27)
1.49 (1.31-1.69) ***
1.73 (1.50-1.99) ***
1.78 (1.51-2.10) ***
2.39 (2.05-2.78) ***
Intracerebral hemorrhage
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.07 (0.72-1.60)
1 (reference)
1.03 (0.85-1.24)
1.08 (0.89-1.32)
1.16 (0.93-1.46)
1.17 (0.89-1.55)
1.23 (0.93-1.61)
Heart failure
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
1.12 (0.91-1.38)
1 (reference)
1.27 (1.16-1.40) ***
1.43 (1.30-1.57) ***
1.79 (1.62-1.98) ***
2.04 (1.82-2.29) ***
2.02 (1.81-2.26) ***
Peripheral arterial disease
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.88 (0.68-1.14)
1 (reference)
1.19 (1.08-1.32) **
1.56 (1.41-1.73) ***
1.75 (1.57-1.96) ***
1.95 (1.72-2.21) ***
2.25 (1.99-2.54) ***
Ventricular arrhythmia or sudden cardiac death
Hazard Ratio
<2
2-3
3-4
4-5
5-6
6-7
0.5 1 2 4
≥ 7
1.24 (0.77-2.01)
1 (reference)
1.16 (0.92-1.46)
1.18 (0.92-1.51)
1.37 (1.04-1.80) *
1.49 (1.07-2.06) *
1.79 (1.3-2.43) **
Abdominal aortic aneurysm
<2
2-3
3-4
4-5
5-6
6-7
≥ 7
0.88 (0.52-1.48)
1 (reference)
1.21 (1.00-1.48)
1.39 (1.14-1.70) **
1.84 (1.49-2.28) ***
1.72 (1.34-2.21) ***
1.74 (1.36-2.24) ***
Hazard Ratio
0.5 1 2 4
Continued on the next page
Shah et al. J A C C V O L . 6 9 , N O . 9 , 2 0 1 7
Neutrophil Counts in Cardiovascular Disease M A R C H 7 , 2 0 1 7 : 1 1 6 0 – 9
1164
J A C C V O L . 6 9 , N O . 9 , 2 0 1 7 Shah et al.
M A R C H 7 , 2 0 1 7 : 1 1 6 0 – 9 Neutrophil Counts in Cardiovascular Disease
1165atrial ﬁbrillation, inﬂammatory conditions (autoim-
mune conditions, chronic obstructive pulmonary
disease, or inﬂammatory bowel disease), cancer,
statin use, blood pressure medication, and acute
conditions at the time of blood testing. The baseline
hazard was stratiﬁed by practice and sex.
We plotted Schoenfeld residuals to assess the pro-
portional hazards assumption, and split the follow-up
time if HRs changed over time. We examined for in-
teractions with age, sex, smoking, and acute clinical
state. We handled missing baseline covariate data by
multiple imputation using random forest (18), as
described in the Online Appendix. We explored addi-
tional adjustments for eosinophil and lymphocyte
counts, which are also associated with incidence of
CVD (14) (each was included as a 5-category variable).
We used a Bonferroni correction for 14 comparisons to
designate the level of statistical signiﬁcance as
0.0036, and expressed p values in categories: <0.05
(suggestive of a trend), <0.0036 (statistically signiﬁ-
cant), and <0.0001 (strong evidence).
RESULTS
We included 621,052 patients with neutrophil counts
while clinically stable and 154,179 patients with
neutrophil counts performed during acute illness or
treatment (Online Figure 1, Online Table 2). We
observed 55,004 initial presentations of CVD over a
median follow-up of 3.8 years (interquartile range
[IQR]: 1.7 to 6.0 years).
Patients with higher neutrophil count were more
likely to smoke, live in a socioeconomically deprived
area, and have comorbidities such as diabetes, asthma,
chronic obstructive pulmonary disease, connective
tissue diseases, and inﬂammatory bowel disease
(Table 1). Patients with neutrophil counts above or
below the limits of normal were more likely to have an
acute state at the time of blood testing than those with
neutrophil counts within the normal range (27.5%
[22,678 of 82,376] vs. 19.0% [131,501 of 692,855];
p < 0.0001). Symptoms or diagnosis of infection were
the most frequent reason for the patient’s condition to
be classiﬁed as acute (Online Table 3). People with
neutrophil counts of 6 to 7  109/l (at the upper end ofFIGURE 2 Continued
Neutrophil count categories inﬂuenced cause-speciﬁc adjusted hazard ra
cardiovascular disease (CVD). Hazard ratios were adjusted for age, sex,
(SBP), blood pressure medication, body mass index (BMI), total choleste
estimated glomerular ﬁltration rate (eGFR), atrial ﬁbrillation (AF), autoi
obstructive pulmonary disease (COPD), cancer, and acute conditions at
**p < 0.0036; ***p < 0.0001. CI ¼ conﬁdence interval; other abbreviathe normal range) had a higher incidence of nonfatal
MI, unheralded coronary death, HF, PAD, and
abdominal aortic aneurysm compared with people
with neutrophil counts of 2 to 3  109/l (Figure 1). The
risk difference appeared to be greatest for the ﬁrst few
months (Online Table 4). Individuals with higher
neutrophil counts were relatively more likely to pre-
sent with unheralded coronary death, HF, or PAD than
stable angina (Online Table 5).
There were strong, speciﬁc associations between
neutrophil counts and different initial presentations
of CVD (Figure 2). Adjusted HRs comparing neutrophil
counts 6 to 7 versus 2 to 3  109/l showed strong as-
sociations with HF (HR: 2.04; 95% conﬁdence interval
[CI]: 1.82 to 2.29), unheralded coronary death (HR:
1.78; 95% CI: 1.51 to 2.10), and nonfatal MI (HR: 1.58;
95% CI: 1.42 to 1.76), but not stable angina (HR: 0.97;
95% CI: 0.88 to 1.07) or unstable angina (HR: 1.00;
95% CI: 0.84 to 1.19) (Figure 2). The association with
ischemic stroke was weak (HR: 1.36; 95% CI: 1.17 to
1.57) and there was no association with hemorrhagic
stroke. There were strong associations with PAD (HR:
1.95; 95% CI: 1.72 to 2.21) and abdominal aortic
aneurysm (HR: 1.72; 95% CI: 1.34 to 2.21) (Figure 2).
The associations were stronger in models adjusted
only for age and sex (Online Figure 2).
There was a strong association of neutrophil count
with noncardiovascular death when comparing
neutrophil counts of 6 to 7 versus 2 to 3  109/l (HR:
2.01; 95% CI: 1.91 to 2.11), with a higher proportion of
deaths due to pneumonia or chronic obstructive pul-
monary disease (Online Table 4). There was also an
association of higher neutrophil count with the com-
posite of CVD (Online Figure 3) and all-cause mortality
(Online Figure 4). Neutrophil counts of <2 109/l were
associated with greater risk of noncardiovascular
death (compared with 2 to 3  109/l: HR: 1.52; 95% CI:
1.41 to 1.63), but were not associated with greater risk
of any presentation of CVD (Online Figure 3).
Because the associations between neutrophil
counts and cardiovascular presentations were
monotonic and linear, we treated neutrophil count
as a linear variable in subsequent modeling. We
found stronger associations within the normal range
(Online Figure 5), but no interaction with smokingtios for cardiovascular presentations among people without prior
deprivation, ethnicity, smoking, diabetes, systolic blood pressure
rol, high-density lipoprotein cholesterol (HDL-C), statin use,
mmune conditions, inﬂammatory bowel disease (IBD), chronic
the time of blood testing. Shaded ¼ normal range. *p < 0.05;
tions as in Figure 1.
FIGURE 3 CVD and Neutrophil Counts by Clinical State at Blood Sampling
Hazard ratio (95% CI) P value forinteractionInitial presentation
Hazard Ratio per 109 Higher Neutrophil Count
0.9 1 1.21.1 1.3
Stable angina
Acute 0.98 (0.96-1.00)
Stable
Mean of 2 stable
1.00 (0.98-1.01)
0.19
0.41.01 (0.99-1.03)
Unstable angina
Acute 0.97 (0.93-1.01)
Stable
Mean of 2 stable
1.02 (0.99-1.05)
0.042
0.871.02 (0.98-1.06)
Coronary disease not further specified
Acute 1.00 (0.97-1.03)
Stable
Mean of 2 stable
1.00 (0.98-1.02)
0.95
0.881.00 (0.97-1.04)
Non fatal myocardial infarction
Acute 1.04 (1.02-1.07) ***
Stable
Mean of 2 stable
1.08 (1.06-1.09) ***
0.016
0.0391.11 (1.08-1.13) ***
Unheralded coronary death
Acute 1.09 (1.06-1.12) ***
Stable
Mean of 2 stable
1.12 (1.10-1.14) ***
0.08
0.0241.16 (1.13-1.20) ***
Heart failure
Acute 1.05 (1.03-1.07) ***
Stable
Mean of 2 stable
1.10 (1.09-1.12) ***
<0.0001
0.00011.16 (1.13-1.18) ***
Ventricular arrhythmia or sudden cardiac death
Acute 1.03 (0.97-1.10)
Stable
Mean of 2 stable
1.08 (1.03-1.12) **
0.24
0.711.09 (1.02-1.17) *
Transient ischemic attack
Acute 1.01 (0.99-1.04)
Stable
Mean of 2 stable
1.04 (1.02-1.06) ***
0.12
0.761.04 (1.02-1.07) **
Ischemic stroke
Acute 1.03 (1.00-1.06)
Stable
Mean of 2 stable
1.05 (1.03-1.07) ***
0.23
0.491.06 (1.03-1.10) **
Stroke not further specified
Acute 1.04 (1.01-1.06) *
Stable
Mean of 2 stable
1.09 (1.07-1.11) ***
0.0012
0.31.11 (1.07, 1.14) ***
Subarachnoid hemorrhage
Acute 1.08 (1.01-1.16) *
Stable
Mean of 2 stable
1.02 (0.96-1.07)
0.15
0.821.00 (0.92-1.09)
Intracerebral hemorrhage
Acute 1.00 (0.94-1.06)
Stable
Mean of 2 stable
1.04 (0.99-1.08)
0.3
0.871.03 (0.96-1.10)
Peripheral arterial disease
Acute 1.07 (1.05-1.09) ***
Stable
Mean of 2 stable
1.12 (1.10-1.14) ***
0.00064
0.0291.15 (1.13-1.18) ***
Abdominal aortic aneurysm
Acute 1.03 (0.99-1.08)
Stable
Mean of 2 stable
1.09 (1.06-1.13) ***
0.042
0.691.11 (1.05-1.17) **
Continued in the next column
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1166status (Online Figure 6). Additional adjustment for
eosinophil and lymphocyte counts did not alter the
estimates (Online Figure 7).
There was some evidence that associations between
neutrophil counts and cardiovascular presentations
were stronger for stable compared with acute mea-
surements, particularly for PAD and HF (Figure 3).
Associations were further strengthened when we used
the mean of 2 consecutive stable neutrophil counts,
which were available in 393,543 patients and were
taken at a median of 1.4 years apart (IQR: 0.6 to 2.7
years) (Figure 3). There was considerable variability
but minimal trend over time between repeat mea-
surements of stable neutrophil counts; the SD of dif-
ferences between 2 consecutive measurements was
1.67  109/l, the correlation coefﬁcient was 0.568, and
the mean rate of change was a decrease of 0.014 per
year (95% CI: 0.011 to 0.017) (Online Figure 8).
We found that hazards were nonproportional for
some of the endpoints. We therefore split the follow-
up time by 6 months, and found that neutrophil
counts were more strongly associated with HF,
unheralded coronary death, and ischemic stroke in
the ﬁrst 6 months (Online Figure 9). Associations with
coronary endpoints, HF, and PAD were stronger
among younger patients (Online Figure 10). The as-
sociation between neutrophil count and initial pre-
sentation with HF was stronger in men than women
(HR per 109/l higher neutrophil count: 1.10 vs. 1.07;
p ¼ 0.001). There was an association between
neutrophil count and initial presentation with tran-
sient ischemic attack in women but not men (HR: 1.05
vs. 1.00; p ¼ 0.007) (Online Figure 11).
DISCUSSION
Neutrophil counts within the range clinicians
currently consider normal had strong linear associa-
tions with some, but not all, CVDs in a population-
based cohort. We found a greater cumulative
incidence of unheralded coronary death, nonfatal MI,
HF, PAD, and abdominal aortic aneurysm in patientsFIGURE 3 Continued
Hazard ratios for initial presentation of CVDs by neutrophil count
varied by clinical state at the time of blood sampling. ‘Mean of
2 stable’ refers to the mean of 2 consecutive neutrophil counts
performed in a stable clinical state. Hazard ratios are adjusted
for age, sex, socioeconomic deprivation, ethnicity, smoking,
diabetes, SBP, blood pressure medication, BMI, total choles-
terol, HDL-C, statin use, eGFR, AF, autoimmune conditions, IBD,
COPD, and cancer. *p < 0.05; **p < 0.0036; ***p < 0.0001.
Abbreviations as in Figures 1 and 2.
CENTRAL ILLUSTRATION Neutrophil Counts
and CVDs
Physical inactivity
Obesity
Genetics
Heart failure
Myocardial infarctionAbdominal aortic aneurysm
Ischemic stroke
Peripheral arterial disease
Putative causal link
suggested by this study
Chronic
inflammation
Thrombosis and
atherosclerosis
High neutrophil count
(may be in ’normal’ range)
Acute inflammation
or infection
Air pollution
Smoking
Shah, A.D. et al. J Am Coll Cardiol. 2017;69(9):1160–9.
Potential causal pathways are depicted linking chronic inﬂammation,
neutrophil counts, and onset of cardiovascular diseases (CVD). Environ-
mental and behavioral risk factors such as smoking, air pollution, and
physical inactivity contribute to chronic inﬂammation. An inﬂammatory
state results in a higher neutrophil count, which may be causally linked
with increased risk of certain cardiovascular conditions.
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1167with neutrophil counts at the upper end of the normal
range (Figure 1), and these associations were
conﬁrmed in multivariable survival models. Our
ﬁndings were consistent with those of previous,
smaller studies that showed a positive association of
higher neutrophil count with HF (6) and a moderate
association with cerebral infarction (7); a key novel
ﬁnding of our study is the association with PAD
and abdominal aortic aneurysm, which has not been
reported previously. In contrast with MI, we found
that neutrophil count was not associated with a
greater incidence of stable or unstable angina. This
study’s large sample size (>700,000 patients) made
it possible to investigate less common CVDs; we
showed lack of association with intracerebral hem-
orrhage and subarachnoid hemorrhage.
SPECIFICITY AND STRENGTH OF ASSOCIATIONS. We
disaggregated CVD into pathologically diverse
initial presentations to help elucidate the mechanistic
role of neutrophils. The stronger association seen
with MI than angina suggests that as well being
involved in inﬂammation and atherosclerosis, neu-
trophils also increase the risk of arterial thrombosis
(Central Illustration). Possible mechanisms include
interactions with the endothelium and platelets, and
overactivity of neutrophil extracellular traps (19).
We also observed associations of higher neutrophil
count with noncardiovascular and overall mortality,
suggesting that chronic inﬂammation has noncardio-
vascular adverse effects that warrant further study.
We examined associations with other leukocyte
subtypes and found that monocyte counts had a
similar pattern of associations with initial pre-
sentations of CVD to neutrophils, but the associations
were not as strong (Online Figure 12). Eosinophil and
lymphocyte counts have a different pattern of associ-
ation with initial presentations of CVD (14), but addi-
tional adjustment for these leukocyte subtypes did not
alter the results for neutrophils (Online Figure 7),
suggesting that these associations are independent.
Neutrophil count has a similar strength and shape
of association with CVD as systolic blood pressure,
with no evidence of a threshold effect among higher
neutrophil counts. A moderate chronic elevation of
systolic blood pressure of 60 mm Hg (e.g., 180 mm Hg
instead of 120 mm Hg) is associated with an approx-
imate doubling of the risk of incident HF (scaled from
Rapsomaniki et al. [11]), which is comparable with the
HR comparing the upper and lower ends of the
normal range for neutrophil count (HR: 2.04; 95% CI:
1.82 to 2.29) (Figure 2).
We also found that associations were stronger
among patients with neutrophil counts taken understable conditions, and when the mean of 2 neutrophil
counts was used; this ﬁnding provides further
evidence for the relevance of a patient’s chronic in-
ﬂammatory state.
TARGETS AND INTERVENTIONS. Reducing chronic
inﬂammation could be a potential therapeutic avenue
in atherosclerotic disease. Our study could not
ascertain whether it is circulating neutrophils per se
that confer the additional risk or the underlying
inﬂammatory state of which the neutrophil count is a
marker (20). Investigation of causal mechanisms
could involve epidemiological studies of upstream
determinants of neutrophil counts, such as gran-
ulocyte colony-stimulating factor, interleukin-17, and
interleukin-23 (21). Mendelian randomization studies
using single nucleotide polymorphisms for genes
associated with neutrophil count, such as those
identiﬁed in the 17q21 region (22), might also help to
evaluate causal relevance.
Colchicine, which has a range of actions on many
cell types, including inhibiting microtubule formation
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Peripheral blood neutrophil counts within the normal
range in people without prior CVD range are associ-
ated linearly with risk of developing MI, ischemic
stroke, HF, peripheral artery disease, and abdominal
aortic aneurysm.
TRANSLATIONAL OUTLOOK: Future
investigations, such as Mendelian randomization
studies, should seek to understand the causal
relevance of neutrophils to various forms of CVD, and
ascertain whether therapies targeting neutrophils
have clinical value in preventing these diseases.
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1168in neutrophils, reduced the incidence of acute coro-
nary syndrome and stroke in a trial among patients
with stable coronary disease (23). Trials are underway
to investigate whether anti-inﬂammatory agents such
as methotrexate (24) or canakinumab (a human
monoclonal antibody against interleukin-1-beta) (25)
can prevent CVD events in high-risk individuals.
Smoking causes an elevation of neutrophil counts
and is associated more strongly with MI than stable
angina (10), like neutrophil counts. A clinical trial of
smoking cessation found that it reduced neutrophil
count by 1.0  109/l (26). We adjusted for smoking in
the main analysis, but if an increased neutrophil
count (or the underlying chronic inﬂammation it
represents) is on a causal pathway linking smoking to
CVD, we might be overadjusting for smoking, thereby
underestimating the component of cardiovascular
risk conveyed by inﬂammation or neutrophils.
Other modiﬁable factors that can increase the level
of chronic low-grade inﬂammation include air pollu-
tion (27), obesity (28), lack of exercise (29), and peri-
odontal disease (30).
STUDY LIMITATIONS. Although our study had
strengths—its large size, population base, and exten-
sive adjustment for potential confounders—it also
had important limitations. Our distinction between
acute and stable patients was crude, but the similarity
of ﬁndings in both groups was reassuring. As with any
observational study, the results cannot be taken to
imply causation due to the possibility of residual
confounding. The measurement of neutrophil counts
was undertaken in usual clinical care, and by
different laboratories without study-wide protocols.
Heterogeneity of measurement methods and hetero-
geneity among the study population itself may have
led to biased estimates of association, but these
would tend to be underestimates. The ascertainment
of endpoints was in coded clinical data without
manual endpoint adjudication. All the data sources
used in this study missed some events (15); however,
any errors in endpoint recording were likely to be
nondifferential in relation to the neutrophil count.
Because our study was based on electronic health
records, some values of baseline variables were
missing for some patients. However, we obtained
similar results by imputing missing data using 2
different methods of multiple imputation.
CLINICAL IMPLICATIONS. Our results suggest that
the current clinical practice of labeling the range of
neutrophil counts 2 to 7  109/l as normal—and
ignoring any risk information conveyed by the actual
value—should be reconsidered. Neutrophil counts area measure of a patient’s chronic inﬂammatory state,
which relates to cardiovascular risk and can be
modiﬁed. Clinicians should look out for treatable
causes of chronic inﬂammation in such patients, such
as periodontal disease (30).
Further research on the associations of neutrophil
counts with CVD is warranted, including investiga-
tion of diurnal and seasonal variations and utility in
risk prediction (20). Other biomarkers of inﬂamma-
tion are associated with greater risk of coronary
disease (3), and U.S. guidelines recommend that high-
sensitivity C-reactive protein can be measured to
inform decisions on cardiovascular risk management
in uncertain cases (31). An advantage of using the
neutrophil count for this purpose, over other inﬂam-
matory biomarkers, is that it is already measured and
would not incur any additional costs for testing.
Third, neutrophil counts could be considered
as a means of monitoring a patient’s progress
or as a surrogate endpoint in trials investigating
anti-inﬂammatory interventions to reduce cardio-
vascular risk.
CONCLUSIONS
Clinically recorded neutrophil counts were strongly
associated with the incidence of speciﬁc CVDs, even
within the normal range. The neutrophil count should
be further evaluated as an inﬂammatory biomarker
relevant to CVD.
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